FDA accepts Kala Pharma's marketing application for Inveltys for ocular inflammation and pain following eye surgery

|About: Kala Pharmaceuticals (KALA)|By:, SA News Editor

The FDA accepts for review Kala Pharmaceuticals' (Pending:KALA) marketing application seeking approval for lead candidate INVELTYS (KPI-121) for the topical treatment of inflammation and pain following ocular surgery. The agency's action date is August 24.

INVELTYS is a twice-daily ocular corticosteroid based on the company's proprietary Mucus Penetrating Particle (MPP) technology, nanoparticles with proprietary coatings that the company says enhances drug penetration and distribution in ocular tissues.

Subscribe for full text news in your inbox